摘要:
This invention relates to a method of electron spin resonance enhanced magnetic resonance imaging which relies on ex vivo dynamic nuclear polarisation of an MR imaging agent.
摘要:
The invention relates to a method of magnetic imaging (MR) of a living sample comprising the steps of hyperpolarizing a hyperpolarizable gas ex-vivo and transferring the nuclear polarization from the hyperpolarized gas to the nuclei of an MR imaging agent, that is not hyperpolarizable, that is exposed to a uniform magnetic field and that is introduced in contact to the hyperpolarizable gas, separating the hyperpolarizable gas from the MR imaging agent, administering the MR imaging agent to the living sample, exciting NMR transitions in the nuclei of the imaging agent and detecting an NMR signal thereof.
摘要:
The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body. The method comprises the step of ex vivo polarization of a high T1 agent. The polarizing agent is optionally separated from the high T1 agent before the high T1 agent is administered to the sample.
摘要:
This invention provides a method of MR investigation of a sample, the method comprising: (i) placing in a uniform magnetic field a composition comprising an OMRI contrast agent and an MR imaging agent containing nuclei (MR imaging nuclei) capable of emitting magnetic resonance signals (e.g. the primary magnetic field B0) and capable of exhibiting a T1 relaxation time of 6 s or more (at 37° C. in D2O in a field of 7T); (ii) exposing the composition to a first radiation of a frequency selected to excite electron spin transitions in the OMRI contrast agent; (iii) optionally but preferably separating the whole, substantially the whole, or a portion of said OMRI contrast agent from said MR imaging agent; (iv) administering said MR imaging agent to said sample, (v) exposing the sample to a second radiation of a frequency selected to excite nuclear spin transitions; (vi) detecting magnetic resonance signals from the sample; and (vii) optionally, generating an image or dynamic flow data from the detected signals.
摘要:
The present invention provides a method of magnetic resonance investigation of a sample, preferably of a human or non-human animal body, said method comprising the step of ex vivo polarisation of a high T1 agent and wherein the polarising agent is optionally seperated from the high T1 agent before the high T1 agent is administered to the sample.
摘要:
The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein n is 0 or 1, and where n is 1 each C.sub.6 R.sub.5 moeity may be the same or different; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M.sub.1, two or three non-adjacent R groups in each C.sub.6 R.sub.5 moiety being iodine and at least one, and preferably two or three, R groups in each C.sub.6 R.sub.5 moiety being M or M.sub.1 moieties; X denotes a bond or a group providing a 1 to 7 atom chain linking two C.sub.6 R.sub.5 moieties or, where n is 0, X denotes a group R; each M independently is a non-ionic hydrophilic moiety; and each M.sub.1 independently represents a C.sub.1-4 alkyl group substituted by at least one hydroxyl group and optionally linked to the phenyl ring via a carbonyl, sulphone or sulphoxide group, at least one R group being an M.sub.1 moiety; with the proviso that where n is zero either at least one M.sub.1 group other than a hydroxymethyl or 1,2-dihydroxyethyl group is present or then if one hydroxymethyl or 1,2-dihydroxyethyl M.sub.1 group is present at least one nitrogen-attached or hydroxylated-C.sub.3-4 alkyl moiety-containing M group is also present) and isomers thereof.
摘要翻译:本发明提供了可用作式I的X射线对比剂的低粘度碘化芳基化合物(其中n为0或1,并且其中n为1,每个C 6 R 5的摩尔可以相同或不同;每个基团R为氢原子 ,碘原子或亲水部分M或M1,每个C 6 R 5部分中两个或三个不相邻的R基团是碘,并且每个C 6 R 5部分中至少一个,优选两个或三个R基团是M或M1部分; X 表示提供连接两个C 6 R 5部分的1至7个原子链的键或基团,或其中n为0,X表示基团R;每个M独立地为非离子亲水部分;并且每个M 1独立地表示C 1-4烷基 至少一个被至少一个羟基取代并且任选地通过羰基,砜或亚砜基团与苯环连接的基团,至少一个R基团是M1部分;条件是其中n为0,或者至少一个除了 存在羟甲基或1,2-二羟乙基, 甲基或1,2-二羟乙基M1基团存在,还存在至少一个含氮连接或羟基化的含C3-4烷基部分的M基团)及其异构体。
摘要:
The invention relates to a modification of electron spin resonance enhanced magnetic resonance imaging (ESREMRI) in which two magnetically responsive materials (contrast agents) are introduced into the sample being investigated, one contrast agent serving as an ESREMRI free induction decay signal enhancing agent and the other as enhancement suppressing agent. In this way, image contrast may be enhanced further for regions in which the suppressing agent distributes poorly or not at all or which the suppressing agent reaches at a later time than the enhancing agent.
摘要:
There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound together with an uptake promoter, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, wherein the uptake promoter comprises a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group or a physiologically tolerable acid containing .alpha.- and/or .beta.- hydroxy or amino groups, or a salt thereof, and/or vitamin D; together with (b) a second contrast agent.Such compositions are particularly suitable for imaging of the liver.
摘要:
There is provided a contrast medium composition comprising: (a) a first contrast agent comprising a physiologically tolerable manganese compound, a physiologically tolerable reducing compound containing an .alpha.-hydroxy ketone group, or salt thereof, having a manganese concentration of at least 0.3 mM or being in a dosage unit form containing at least 300 .mu.mol manganese, together with (b) a second contrast agent. Such compositions have been found to be particularly suited to imaging of the liver.
摘要:
The present invention provides a method of MR investigation of a sample, said method comprising: (i) nuclear spin polarizing a high T1 MR imaging agent which contains in its molecular structure at least two hyperpolarisable nuclei within the same molecule, the frequency difference between the two resonance lines from said nuclei, δυ, being dependent upon either the temperature or the pH of said sample; (ii) administering the nuclear spin polarized MR imaging agent to said sample; (iii) exposing said sample to a radiation at a frequency selected to excite nuclear spin transitions in said MR imaging agent; and (iv) detecting and manipulating magnetic resonance signals from said sample using a single-shot RARE acquisition sequence with shifted data acquisition.